Kiora Pharmaceuticals, Inc. appointed Susan L. Drexler as Interim Chief Financial Officer of the Company, effective as of the Effective Date. Ms. Drexler will also serve as the Company's principal accounting officer and principal financial officer. Ms. Drexler, age 52, has extensive experience as a chief financial officer, with over 25 years of experience with development and commercial stage life science companies.

Since January 2022, Ms. Drexler has served as a consultant with Danforth Advisors, LLC (“Danforth”), a provider of strategic and operational finance and accounting for life science companies, and, since March 2022, she has served as a financial consultant to the Company's pursuant to a consulting agreement between the Company and Danforth dated as of March 9, 2022 (the “Consulting Agreement”). Previously, Ms. Drexler served as Chief Financial Officer of Harmony Biosciences Holdings, Inc. (Nasdaq:HRMY) from October 2019 through March 2021. Ms. Drexler also served as Acting Chief Financial Officer and Vice President, Business Development of Ocugen, Inc. from April 2018 through June 2019 and in senior Business Development and Market Intelligence roles at AmerisourceBergen Drug Corporation from August 2015 through November 2017, including as Vice President, Business Development and Market Intelligence.

Ms. Drexler previously served as Director, Corporate Finance of Shire Pharmaceuticals from 2007 through 2015. She received a B.S. in Accounting from Albright College and an MBA in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Pursuant to the Consulting Agreement, Ms. Drexler will provide services to the Company as an independent contractor and employee of Danforth.

The Consulting Agreement may be terminated by the Company or Danforth (a) with cause (as defined in the Consulting Agreement), upon 30 days' prior written notice to the other party or (b) without cause upon 60 days' prior written notice to the other party. Pursuant to the Consulting Agreement, Danforth will receive cash compensation at a rate of $450 per hour for Ms. Drexler's services. There is no family relationship between Ms. Drexler and any director or executive officer of the Company.

There are no transactions between Ms. Drexler and the Company that would be required to be reported under Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended.